Matt Reynolds

@mattreynolds.bsky.social

Director of Communications at Forecasting Research Institute // matt@forecastingresearch.org // Previously @wired.com‬ @newscientist.com‬

My final piece for @wired.com A story of biotech and betrayal, based on thousands of court documents, depositions, testimony and interviews. Featuring an Argentine polo star, a Texas oilman and an exiled Russian billionaire. Oh, and lots and lots of cloned horses. www.wired.com/story/clonin...

Cloning Came to Polo. Then Things Got Truly Uncivilized

A polo legend and a businessman joined forces to copy the player’s greatest horse. But with a single clone worth $800,000, some technologies are a breeding ground for betrayal.

wired.com

Some *personal news* I'm the new Director of Communications at @Research_FRI I'll be getting the word out on how the science of forecasting can help decision-makers approach high-stake issues, such as AI, nuclear and bio risks.

WARNING: Yesterday, my X account (@JKFruit) was compromised and used to promote an inauthentic WIRED-branded crypto coin. Please disregard any further posts made to that account.

I've seen lots of photos of houses that survived the LA fires while others burned—but rebuilding should be about making whole communities more defensible against wildfire. And that means having some tough conversations about where to build, and whether to build at all www.wired.com/story/how-to...

Los Angles Needs to Fireproof Communities, Not Just Houses

After the devastation of the Los Angeles fires, officials are ready to rebuild. But defending against future fires requires thinking about more than buildings.

wired.com

Stem cell treatments favoured by anti-ageing evangelist Bryan Johnson start at $16,500, but the donors who provide the key ingredient are paid just $200 Each donor provides enough cells to be used in millions of dollars worth of treatments. www.wired.com/story/stem-c...

These Stem Cell Treatments Cost the Rich Thousands. Donors Get Paid $200

A Swedish startup wants to democratize stem cell treatments, but the finances of the unproven therapies raise ethical questions.

wired.com